1. Polypharmacy and health outcomes in atrial fibrillation: a systematic review and meta-analysis
- Author
-
Melissa E Middeldorp, Dennis H Lau, Christopher X Wong, Debra Rowett, Karin Nyfort-Hansen, Prash Sanders, and Jeroen M Hendriks
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
ObjectiveTo undertake a systematic review and meta-analysis examining the impact of polypharmacy on health outcomes in atrial fibrillation (AF).Data sourcesPubMed and Embase databases were searched from inception until 31 July 2019. Studies including post hoc analyses of prospective randomised controlled trials or observational design that examined the impact of polypharmacy on clinically significant outcomes in AF including mortality, hospitalisations, stroke, bleeding, falls and quality of life were eligible for inclusion.ResultsA total of six studies were identified from the systematic review, with three studies reporting on common outcomes and used for a meta-analysis. The total study population from the three studies was 33 602 and 37.2% were female. Moderate and severe polypharmacy, defined as 5–9 medicines and >9 medicines, was observed in 42.7% and 20.7% of patients respectively, and was associated with a significant increase in all-cause mortality (Hazard ratio [HR] 1.36, 95% CI 1.20 to 1.54, p
- Published
- 2020
- Full Text
- View/download PDF